key: cord-0838996-puxqaroj authors: Hakamifard, Atousa; Hashemi, Marzieh; Fakhim, Hamed; Aboutalebian, Shima; Hajiahmadi, Somayeh; Mohammadi, Rasoul title: Fatal disseminated aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus ochraceus date: 2021-02-23 journal: J Mycol Med DOI: 10.1016/j.mycmed.2021.101124 sha: 8586b9271ceb84a35abd7e28ebe8f9753cdf7dd8 doc_id: 838996 cord_uid: puxqaroj Aspergillus infection is a well-known complication of severe influenza and severe acute respiratory syndrome coronavirus (SARS-CoV), and these infections have been related with significant morbidity and mortality even when appropriately diagnosed and treated. Recent studies have indicated that SARS-CoV-2 might increase the risk of invasive pulmonary aspergillosis (IPA). Here, we report the first case of Aspergillus ochraceus in a SARS-CoV-2 positive immunocompetent patient, which is complicated by pulmonary and brain infections. Proven IPA is supported by the positive galactomannan test, culture-positive, and histopathological evidence. The patient did not respond to voriconazole, and liposomal amphotericin B was added to his antifungal regimen. Further studies are needed to evaluate the prevalence of IPA in immunocompetent patients infected with SARS-CoV-2. Consequently, testing for the incidence of Aspergillus species in lower respiratory secretions and galactomannan test of COVID-19 patients with appropriate therapy and targeted antifungal therapy based on the primary clinical suspicion of IPA are highly recommended. Aspergillus species is considered one of the main causes of life-threatening infections in hospitalized patients with significant morbidity and mortality rates even when appropriately diagnosed and treated [1] [2] [3] [4] . The clinical spectrum of these fungi causes various infections, ranging from allergic and chronic infections to acute invasive aspergillosis (IA) [1, 2] . The incidence of this infection has increased in recent years, especially among hematopoietic stem cell recipients, solid organ transplant recipient, chronic pulmonary infections, and patients with severe influenza pneumonia [5] [6] . Previous studies indicated that influenza and coronavirus disease 2019 (COVID- 19) were associated with an increased risk for invasive aspergillosis [7] [8] [9] [10] . They are also complicated by invasive pulmonary aspergillosis (IPA) in 6-24% of cases with a high mortality rate of over 45% [11] . Recent studies have demonstrated that coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 may increase the risk of superinfections [7, 12] and particularly IPA coinfection [13, 14] . As recent studies have revealed, IPA emerges among SARS-CoV-2 infected patients in intensive care units (ICUs) with severe pulmonary abnormalities [15, 16] . Furthermore, COVID-19 associated pulmonary aspergillosis (CAPA) was reported in many countries [14, 17, 18] . Here, we present the first case of Aspergillus ochraceus in a SARS-CoV-2 positive immunocompetent patient in Isfahan, Iran. In June 2020, a 35-year-old immunocompetent man with a fever (38.5 °C) for six days, myalgia, dry cough, loss of appetite, and dyspnea with oxygen saturation (SpO2) of 88% on room air was admitted to the Emergency Department, Isfahan University of Medical Sciences, Isfahan, Iran. Laboratory results showed leukopenia (900/mm 3 shortness of breath and cough. Chest X ray ( Fig. 1A -B) and chest CT scan ( Fig. 2A-B) showed parenchymal consolidation and soft tissue attenuated nodules with a random distribution. The patient was transferred to the intensive care unit (ICU) due to oxygen saturation of 87% on room air, dyspnea and severe bilateral pulmonary infiltrates (day 25). Laboratory analysis revealed white blood cell 3200 mm 3 , hemoglobin 13.5 g/dl, neutrophil 72.6%, lymphocytes 17%, platelets 242000 mm 3 , blood urea nitrogen 11 mg/dl, and creatinine 0.8 mg/dl. Considering clinical manifestation, laboratory data and lung CT scan, meropenem (2g/8h) and vancomycin (1g/12h) were started. According to multiple nodules with a random distribution in the chest CT scan, intravenous 3') and sequenced as previously described [19] . The DNA sequence of the beta-tubulin gene was subjected to a BLAST search of the NCBI databases. The isolate was identified as Aspergillus ochraceus, having 99% sequence identity. The molecular results confirmed the mycological diagnosis of the disease as disseminated aspergillosis due to Aspergillus ochraceus. The betatubulin gene sequence of the strain from the current case has been deposited in the GenBank under the accession number MT799706. Antifungal susceptibility tests, using broth microdilution, were performed according to the Clinical and Laboratory Standard Institute methods [20] . The MIC values were as follows: amphotericin B (1 μg/mL), itraconazole (0.5 μg/mL), voriconazole (0.5 μg/mL), caspofungin (0.016 μg/mL), anidulafungin (0.008 μg/mL) and micafungin (0.008 μg/mL). Liposomal amphotericin B (5 mg/kg/day) was added to his antifungal regimen, and meropenem and vancomycin were stopped. On day 40, despite antifungal therapy, the patient died 16 days after hospital admission due to respiratory distress and pulmonary failure (Fig. 5) . This research was approved by the Ethics Committee of Isfahan University of Medical Science (no. IR.MUI.MED.REC.1399.343), and written informed consent was obtained from the patient. Since January 27, 2021, the COVID-19 pandemic due to SARS-CoV-2 has thus far killed over 57,651 people and infected over 1,392,314 individuals in Iran. Recent studies have shown that CAPA may occur in the immunocompetent host. We report the first case of Aspergillus ochraceus in a SARS-CoV-2 positive, which occurred in an immunocompetent host without an underlying condition. Most immunocompetent patients presenting severe types of COVID-19 have at least one underlying condition, such as diabetes mellitus, chronic obstructive pulmonary disease, chronic renal disease, and hypertension [21] ; however, none of these risk factors is commonly associated with an increased risk for invasive fungal infections. In our patient, the WBC count was 900 per μl (with 90% neutrophil) at first admission with the diagnosis of COVID-19, which was 2100 per μl on day 3. On day 25, at second hospitalization, the WBC count was 3200 per μl (with neutrophil 72.6%). In both times, the patient had leukopenia due to COVID-19 infection as a viral infection. Furthermore, the patient had not prolonged neutropenia as a risk factor for invasive aspergillosis, and it was transient on the first admission. At second hospitalization the patient was not neutropenic. Blaize, et al. [22] reported a case of invasive aspergillosis in an immunocompetent male with severe COVID-19-associated pneumonia with several underlying chronic diseases, such as myelodysplastic syndrome and Hashimoto's thyroiditis. In the absence of host factors, as defined by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria for invasive aspergillosis, invasive or high-risk diagnostic methods, such as CT scan and biopsy, are essential to support the recognition of IPA [23] . The IPA in ICU Page 6 of 10 J o u r n a l P r e -p r o o f 6 patients is recognized as a valid algorithm to comparatively deal with the absence of host factors [24] . Bartoletti et al. recommended that CAPA criteria for diagnosis of invasive aspergillosis might provide earlier diagnosis than AspICU criteria and might prioritize prompt antifungal treatment [25] . The present case was diagnosed with proven CAPA, based on the positive galactomannan test, culture-positive, and histopathological evidence [26] . Overall, cerebral aspergillosis has a high mortality rate, and survivors present various neurological deficiencies [27] . Aspergillus ochraceus has not been reported as a frequent causative agent of pulmonary infections, especially among asthmatic and immunocompromised patients. In this regard, Negri et al. showed that only one out of 133 patients was found to have A. ochraceus infection [28] . Similarly, Carpagnano et al. revealed colonization with A. ochraceus in only three of 43 cancer patients [29] . Moazam et al. [30] reported a 39-year-old male case with chronic pulmonary aspergillosis (CPA) due to A. ochraceus with a history of chronic obstructive pulmonary disease (COPD). Contrary to the present case, he was healed and responded well to IV voriconazole. Overall, SARS-CoV-2 may be a risk factor for IA and other invasive fungal diseases [12] . Our case report highlights that clinical suspicion and screening are needed to evaluate the prevalence of IPA in immunocompetent patients infected with COVID-19. Consequently, testing for the presence of Aspergillus species in lower respiratory secretions, and the GM test in COVID-19 patients, as well as primary clinical suspicion of IPA with appropriate and targeted antifungal therapy according to national and international guidelines are highly recommended. The authors declare that they have no competing interest. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group The clinical spectrum of pulmonary aspergillosis Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes Invasive aspergillosis in critically ill patients without malignancy Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET) Fatal invasive pulmonary aspergillosis in COVID-19 patient with acute myeloid leukemia in Iran Fatal aspergillosis in a patient with SARS who was treated with corticosteroids Influenza-associated Aspergillosis in Critically Ill Patients Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: a retrospective cohort study from Alberta Invasive fungal diseases during COVID-19: We should be prepared Diagnosing COVID-19-associated pulmonary aspergillosis Associated Pulmonary Aspergillosis Invasive pulmonary aspergillosis complicating COVID-19 in the ICU-A case report COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan COVID-19 associated pulmonary aspergillosis Prevalence of putative invasive pulmonary aspergillosis in critically ill COVID-19 patients β-tubulin paralogue tubC is frequently misidentified as the benA gene in Aspergillus section Nigri taxonomy: primer specificity testing and taxonomic consequences Reference Method For Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance Magnetic resonance imaging of cerebral aspergillosis: imaging and pathological correlations Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles Aspergillus spp. colonization in exhaled breath condensate of lung cancer patients from Puglia Region of Italy Aspergillus nodules in chronic granulomatous disease attributable to Aspergillus ochraceus This study was financially supported by a grant from the School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran (no. 199163), which we gratefully acknowledge.